

# Ashish M Kamat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8878964/publications.pdf>

Version: 2024-02-01

340  
papers

15,273  
citations

17440

63  
h-index

26613

107  
g-index

408  
all docs

408  
docs citations

408  
times ranked

12014  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Bladder cancer. <i>Lancet</i> , The, 2016, 388, 2796-2810.   | 13.7 | 1,031     |
| 2  | Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. <i>Journal of Urology</i> , 2017, 198, 552-559.  | 0.4  | 632       |
| 3  | Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018, 74, 784-795.  | 1.9  | 530       |
| 4  | Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. <i>Clinical Cancer Research</i> , 2010, 16, 2861-2871.  | 7.0  | 404       |
| 5  | Definitions, End Points, and Clinical Trial Designs for Non-muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 1935-1944.  | 1.6  | 279       |
| 6  | Micropapillary bladder cancer. <i>Cancer</i> , 2007, 110, 62-67.   | 4.1  | 253       |
| 7  | Focus on bladder cancer. <i>Cancer Cell</i> , 2004, 6, 111-116.  | 16.8 | 252       |
| 8  | Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 919-930.   | 10.7 | 239       |
| 9  | A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016, 69, 855-862. | 1.9  | 228       |
| 10 | ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.   | 1.9  | 225       |
| 11 | Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 925-933.  | 1.9  | 209       |
| 12 | The Case for Early Cystectomy in the Treatment of Nonmuscle Invasive Micropapillary Bladder Carcinoma. <i>Journal of Urology</i> , 2006, 175, 881-885.   | 0.4  | 194       |
| 13 | Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.  | 30.7 | 193       |
| 14 | Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. <i>European Urology</i> , 2014, 66, 265-272.  | 1.9  | 186       |
| 15 | Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , The, 2021, 22, 107-117.   | 10.7 | 172       |
| 16 | An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously) T1a and T1b Urothelial Carcinoma. <i>Journal of Urology</i> , 2019, 199, 169-175.  | 1.9  | 169       |
| 17 | Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014, 120, 1794-1799.  | 4.1  | 154       |
| 18 | Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2014, 191, 40-47.   | 0.4  | 153       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor- $\kappa$ B and nuclear factor- $\kappa$ B-regulated gene products in IFN- $\gamma$ -sensitive and IFN- $\gamma$ -resistant human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1022-1030. | 4.1 | 152       |
| 20 | Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2592-2597.  | 1.6 | 148       |
| 21 | Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. <i>European Urology</i> , 2013, 64, 307-313.   | 1.9 | 147       |
| 22 | Differences in Survival Among Patients With Sarcomatoid Carcinoma, Carcinosarcoma and Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2007, 178, 2302-2307.   | 0.4 | 146       |
| 23 | Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015, 12, 225-235.  | 3.8 | 139       |
| 24 | Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014, 23, 1387-1398.   | 2.9 | 137       |
| 25 | Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. <i>European Urology</i> , 2016, 69, 197-200.   | 1.9 | 136       |
| 26 | EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.  | 1.9 | 132       |
| 27 | What Is the Significance of Variant Histology in Urothelial Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 653-663.  | 3.1 | 126       |
| 28 | Intravesical rAd $\gamma$ -IFN $\gamma$ /Syn3 for Patients With High-Grade, Bacillus Calmette-Guérin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3410-3416.  | 1.6 | 124       |
| 29 | Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018, 73, 738-748.  | 1.9 | 112       |
| 30 | Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020, 78, 893-906.   | 1.9 | 112       |
| 31 | Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.   | 1.9 | 110       |
| 32 | BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. <i>Nature Reviews Urology</i> , 2017, 14, 244-255.   | 3.8 | 108       |
| 33 | Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. <i>Urology</i> , 2007, 70, 252-256.  | 1.0 | 107       |
| 34 | The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 543-557.  | 1.9 | 105       |
| 35 | Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). <i>Journal of Clinical Oncology</i> , 2019, 37, 350-350.  | 1.6 | 103       |
| 36 | Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. <i>Cell Reports</i> , 2019, 27, 1781-1793.e4.   | 6.4 | 102       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon- $\beta$ Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2013, 190, 850-856.   | 0.4 | 101       |
| 38 | Clinical Outcomes of cT1 Micropapillary Bladder Cancer. <i>Journal of Urology</i> , 2015, 193, 1129-1134.  | 0.4 | 101       |
| 39 | Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. <i>Journal of Urology</i> , 2014, 191, 20-27.  | 0.4 | 98        |
| 40 | Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020, 26, 882-891.   | 7.0 | 98        |
| 41 | 1,1-Bis(3-indolyl)-1-(4-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3825-3833.  | 4.1 | 95        |
| 42 | Curcumin Potentiates the Antitumor Effects of Bacillus Calmette-Guerin against Bladder Cancer through the Downregulation of NF- $\kappa$ B and Upregulation of TRAIL Receptors. <i>Cancer Research</i> , 2009, 69, 8958-8966.  | 0.9 | 95        |
| 43 | Evaluation of the Relevance of Lymph Node Density in a Contemporary Series of Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2006, 176, 53-57.  | 0.4 | 94        |
| 44 | Inhibition of Bladder Tumor Growth by 1,1-Bis(3-Indolyl)-1-(p-Substitutedphenyl)Methanes: A New Class of Peroxisome Proliferator-Activated Receptor $\beta$ Agonists. <i>Cancer Research</i> , 2006, 66, 412-418.  | 0.9 | 93        |
| 45 | What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 625-642. | 5.4 | 88        |
| 46 | Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). <i>BJU International</i> , 2013, 112, 742-750.  | 2.5 | 87        |
| 47 | Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. <i>Urology</i> , 2004, 63, 46-50.   | 1.0 | 86        |
| 48 | Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder. <i>Cancer</i> , 2007, 110, 764-769.   | 4.1 | 84        |
| 49 | Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. <i>Urology</i> , 2014, 83, 863-868.   | 1.0 | 82        |
| 50 | Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 305-315.   | 0.4 | 82        |
| 51 | Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinat in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018, 199, 1158-1165.   | 0.4 | 82        |
| 52 | 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , 2021, 18, 611-622.   | 3.8 | 80        |
| 53 | Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial. <i>Journal of Urology</i> , 2012, 187, 862-867.  | 0.4 | 78        |
| 54 | Urachal carcinoma: a pathologic and clinical study of 46 cases. <i>Human Pathology</i> , 2015, 46, 1808-1814.  | 2.0 | 78        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. <i>Bladder Cancer</i> , 2015, 1, 29-30.   | 0.4 | 75        |
| 56 | Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-Guérin. <i>Journal of Urology</i> , 2015, 193, 1135-1143.          | 0.4 | 75        |
| 57 | A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer. <i>Cancer</i> , 2013, 119, 540-547. | 4.1 | 74        |
| 58 | Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. <i>World Journal of Urology</i> , 2017, 35, 337-353.   | 2.2 | 74        |
| 59 | Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. <i>JAMA Surgery</i> , 2018, 153, 881.   | 4.3 | 73        |
| 60 | Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020, 78, 719-730.                    | 1.9 | 73        |
| 61 | Clinical Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1048-1056.     | 0.8 | 71        |
| 62 | Hexaminolevullinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014, 11, 589-596.                  | 3.8 | 69        |
| 63 | Nonurothelial Bladder Cancer and Rare Variant Histologies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 237-252.   | 2.2 | 68        |
| 64 | Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.   |     | 68        |
| 65 | Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. <i>BJU International</i> , 2011, 108, 1119-1123.   | 2.5 | 64        |
| 66 | Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. <i>Urology</i> , 2009, 73, 147-152.  | 1.0 | 63        |
| 67 | The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 279-90.  | 4.1 | 63        |
| 68 | CHEMOPREVENTION OF UROLOGICAL CANCER. <i>Journal of Urology</i> , 1999, 161, 1748-1760.   | 0.4 | 62        |
| 69 | P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. <i>European Urology</i> , 2007, 52, 769-776.  | 1.9 | 61        |
| 70 | Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. <i>European Urology</i> , 2018, 74, 597-608.   | 1.9 | 61        |
| 71 | COVID-19 and Bacillus Calmette-Guérin: What is the Link?. <i>European Urology Oncology</i> , 2020, 3, 259-261.  | 5.4 | 61        |
| 72 | Follow-up in non-muscle-invasive bladder cancer International Bladder Cancer Network recommendations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 460-468.   | 1.6 | 60        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Total Pelvic Exenteration: Effective Palliation of Perineal Pain in Patients With Locally Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2003, 170, 1868-1871.   | 0.4 | 59        |
| 74 | Alvimopan, a Peripherally Acting $\hat{1}/4$ -Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial. <i>Journal of Urology</i> , 2014, 191, 1721-1727.                    | 0.4 | 56        |
| 75 | Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection. <i>Journal of Urology</i> , 2011, 185, 79-84.  | 0.4 | 55        |
| 76 | Intravesical therapy for bladder cancer. <i>Urology</i> , 2000, 55, 161-168.   | 1.0 | 53        |
| 77 | Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. <i>American Journal of Clinical Pathology</i> , 2017, 147, 500-506.  | 0.7 | 52        |
| 78 | Variant histology. <i>Current Opinion in Urology</i> , 2014, 24, 517-523.  | 1.8 | 51        |
| 79 | Differential expression of GATA-3 in urothelial carcinoma variants. <i>Human Pathology</i> , 2014, 45, 1466-1472.  | 2.0 | 51        |
| 80 | Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 59.e1-59.e8. | 1.6 | 51        |
| 81 | Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2017, 3, 258-264.   | 3.1 | 51        |
| 82 | Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA " update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.                      | 3.8 | 51        |
| 83 | Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. <i>Cancer</i> , 2010, 116, 340-346.   | 4.1 | 49        |
| 84 | Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF- $\hat{1}$ but not through TRAIL and FasL. <i>Journal of Leukocyte Biology</i> , 2012, 92, 233-244.   | 3.3 | 49        |
| 85 | Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. <i>Communications Medicine</i> , 2022, 2, .  | 4.2 | 49        |
| 86 | Micropapillary bladder cancer: Current treatment patterns and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 826-832.  | 1.6 | 48        |
| 87 | Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. <i>Human Pathology</i> , 2018, 79, 57-65.   | 2.0 | 48        |
| 88 | Recurrence mechanisms of non-muscle-invasive bladder cancer " a clinical perspective. <i>Nature Reviews Urology</i> , 2022, 19, 280-294.   | 3.8 | 48        |
| 89 | Antitumor activity of common antibiotics against superficial bladder cancer. <i>Urology</i> , 2004, 63, 457-460.   | 1.0 | 47        |
| 90 | Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. <i>Scientific Reports</i> , 2017, 7, 9602.   | 3.3 | 47        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. <i>Future Oncology</i> , 2020, 16, 507-516.   | 2.4 | 47        |
| 92  | Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.   | 2.7 | 47        |
| 93  | The Impact of Blue Light Cystoscopy with Hexaminolevulinat (HAL) on Progression of Bladder Cancer – A New Analysis. <i>Bladder Cancer</i> , 2016, 2, 273-278.   | 0.4 | 46        |
| 94  | Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018, 1, 91-100.   | 5.4 | 46        |
| 95  | Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-muscle-Invasive Bladder Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 1235-1245.  | 1.5 | 45        |
| 96  | Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. <i>Current Stem Cell Research and Therapy</i> , 2014, 9, 89-101.  | 1.3 | 44        |
| 97  | Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. <i>Journal of Urology</i> , 2008, 180, 164-167.   | 0.4 | 42        |
| 98  | Should histologic variants alter definitive treatment of bladder cancer?. <i>Current Opinion in Urology</i> , 2013, 23, 435-443.  | 1.8 | 42        |
| 99  | Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 3-13.  | 2.2 | 42        |
| 100 | Uroplakin II Is a More Sensitive Immunohistochemical Marker Than Uroplakin III in Urothelial Carcinoma and Its Variants. <i>American Journal of Clinical Pathology</i> , 2014, 142, 864-871.  | 0.7 | 41        |
| 101 | Fluorescence in situ hybridization for detecting urothelial carcinoma. <i>Cancer Cytopathology</i> , 2010, 118, 259-268.  | 2.4 | 40        |
| 102 | Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625. | 2.5 | 40        |
| 103 | Diagnostic Accuracy of Novel Urinary Biomarker Tests in non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.   | 5.4 | 40        |
| 104 | Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1061-1068.  | 1.6 | 39        |
| 105 | Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016, 25, 1203-1214.  | 2.9 | 38        |
| 106 | Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. <i>European Urology Oncology</i> , 2020, 3, 622-630.  | 5.4 | 38        |
| 107 | Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. <i>Cancer</i> , 2018, 124, 3127-3135.   | 4.1 | 37        |
| 108 | Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer. <i>European Urology</i> , 2014, 65, 267-269.   | 1.9 | 36        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <i>BJU International</i> , 2017, 119, 684-691.  | 2.5 | 36        |
| 110 | Immunotherapy for bladder cancer. <i>Current Urology Reports</i> , 2001, 2, 62-69.   | 2.2 | 35        |
| 111 | Atorvastatin: A potential chemopreventive agent in bladder cancer. <i>Urology</i> , 2005, 66, 1209-1212.   | 1.0 | 35        |
| 112 | Novel fluorescence <i>in situ</i> hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. <i>BJU International</i> , 2016, 117, 754-760.  | 2.5 | 35        |
| 113 | Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. <i>Cancers</i> , 2021, 13, 4378. | 3.7 | 35        |
| 114 | Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1069-1077.   | 1.6 | 34        |
| 115 | Advances in risk stratification of bladder cancer to guide personalized medicine. <i>F1000Research</i> , 2018, 7, 1137.  | 1.6 | 34        |
| 116 | Chemoprevention for Bladder Cancer. <i>Journal of Urology</i> , 2006, 176, 1914-1920.  | 0.4 | 33        |
| 117 | Bladder Cancer Stem Cells. <i>Current Stem Cell Research and Therapy</i> , 2010, 5, 387-395.   | 1.3 | 33        |
| 118 | Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. <i>Cancer Biology and Therapy</i> , 2010, 10, 885-892.  | 3.4 | 33        |
| 119 | The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 821-824.   | 1.6 | 33        |
| 120 | Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 772-780.   | 1.6 | 33        |
| 121 | Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. <i>Journal of Endourology</i> , 2017, 31, 946-953.   | 2.1 | 33        |
| 122 | Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. <i>Future Oncology</i> , 2019, 15, 1323-1334.   | 2.4 | 33        |
| 123 | Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. <i>World Journal of Urology</i> , 2019, 37, 2017-2029.  | 2.2 | 33        |
| 124 | Genetic Variants in the Wnt/ $\beta$ 2-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. <i>Journal of Urology</i> , 2015, 194, 1771-1776.   | 0.4 | 32        |
| 125 | Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 413-422.   | 1.6 | 32        |
| 126 | The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e17-353.e24.  | 1.6 | 32        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | What is new in non-muscle-invasive bladder cancer in 2016?. Turkish Journal of Urology, 2017, 43, 9-13.  | 1.3 | 32        |
| 128 | Chemoprevention of bladder cancer. Urologic Clinics of North America, 2002, 29, 157-168.   | 1.8 | 31        |
| 129 | Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. European Urology, 2019, 75, 8-10.   | 1.9 | 31        |
| 130 | Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). BJU International, 2020, 125, 497-505.   | 2.5 | 31        |
| 131 | Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. European Urology Oncology, 2021, 4, 893-903.  | 5.4 | 31        |
| 132 | Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. Journal of Urology, 2021, 205, 1612-1621.  | 0.4 | 31        |
| 133 | Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.  | 0.4 | 30        |
| 134 | Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 2020, 77, 669-670.  | 1.9 | 30        |
| 135 | International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. European Urology, 2022, 82, 34-46.                            | 1.9 | 30        |
| 136 | Re: Aurélie Kamoun, Aurélien de Reyni's, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33. European Urology, 2020, 77, e105-e106.   | 1.9 | 29        |
| 137 | Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU International, 2018, 122, 89-98.   | 2.5 | 28        |
| 138 | Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surgery, 2019, 154, e191629.  | 4.3 | 28        |
| 139 | Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. European Urology, 2020, 78, 387-399.                                    | 1.9 | 28        |
| 140 | Role of Checkpoint Inhibition in Localized Bladder Cancer. European Urology Oncology, 2018, 1, 190-198.  | 5.4 | 26        |
| 141 | Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 318-340. | 5.4 | 26        |
| 142 | Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. European Urology Oncology, 2021, 4, 12-19.  | 5.4 | 26        |
| 143 | The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guérin vaccination: a robust ecological analysis using unsupervised machine learning. Scientific Reports, 2021, 11, 774.  | 3.3 | 26        |
| 144 | Identification of Factors Predicting Response to Adjuvant Radiation Therapy in Patients With Positive Margins After Radical Prostatectomy. Journal of Urology, 2003, 170, 1860-1863.   | 0.4 | 25        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | Statins and the Effect of BCG on Bladder Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 1276-1277.  | 27.0 | 25        |
| 146 | Definition and management of patients with bladder cancer who fail BCG therapy. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 815-820.   | 2.4  | 25        |
| 147 | Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. <i>European Urology</i> , 2016, 70, 778-785.   | 1.9  | 25        |
| 148 | Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 437-451.  | 1.6  | 25        |
| 149 | Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. <i>European Urology Oncology</i> , 2018, 1, 223-230.  | 5.4  | 25        |
| 150 | Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019, 2, 355-364.   | 5.4  | 25        |
| 151 | Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. <i>European Urology Focus</i> , 2020, 6, 88-94.   | 3.1  | 25        |
| 152 | Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5041-5041. | 1.6  | 25        |
| 153 | VALIDATION OF CRITERIA USED TO PREDICT EXTRAPROSTATIC CANCER EXTENSION: A TOOL FOR USE IN SELECTING PATIENTS FOR NERVE SPARING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 1262-1265.  | 0.4  | 24        |
| 154 | Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. <i>Oncolmmunology</i> , 2012, 1, 1161-1162.  | 4.6  | 24        |
| 155 | A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. <i>BMC Medical Research Methodology</i> , 2015, 15, 45.                      | 3.1  | 24        |
| 156 | Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. <i>Cell Death Discovery</i> , 2016, 2, .   | 4.7  | 24        |
| 157 | Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients. <i>Bladder Cancer</i> , 2017, 3, 65-71.  | 0.4  | 24        |
| 158 | Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. <i>European Urology Oncology</i> , 2022, 5, 84-91.         | 5.4  | 24        |
| 159 | Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2014, 84, 1147-1151.   | 1.0  | 23        |
| 160 | Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. <i>Cancer Causes and Control</i> , 2017, 28, 755-766.  | 1.8  | 23        |
| 161 | Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making. <i>Urology</i> , 2017, 110, 76-83.  | 1.0  | 23        |
| 162 | Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2018, 4, 720-724.  | 3.1  | 23        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 497-504.  | 5.4 | 23        |
| 164 | Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-muscle-invasive Bladder Cancer Among Older Adults, 2004-2013. <i>JAMA Network Open</i> , 2022, 5, e223050.  | 5.9 | 23        |
| 165 | Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon $\beta$ Formulated in Syn3 for Failures of Bacillus Calmette-Guérin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 4110-4114. | 1.5 | 22        |
| 166 | Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 – what’s old is new again?. <i>Future Oncology</i> , 2020, 16, 1323-1325.  | 2.4 | 22        |
| 167 | Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. <i>Cancer</i> , 2006, 107, 1491-1495.   | 4.1 | 21        |
| 168 | Considerations on the use of diagnostic markers in management of patients with bladder cancer. <i>World Journal of Urology</i> , 2008, 26, 39-44.   | 2.2 | 21        |
| 169 | CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatment Strategy for Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 79-88.   | 0.4 | 21        |
| 170 | Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patients undergoing urologic oncology surgery: a systematic review. <i>World Journal of Urology</i> , 2022, 40, 1325-1342.  | 2.2 | 21        |
| 171 | Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the Bladder. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 1027-1036.   | 4.9 | 20        |
| 172 | Novel PKC- $\eta$ to p47phox interaction is necessary for transformation from blebbistatins. <i>Scientific Reports</i> , 2016, 6, 23965.  | 3.3 | 20        |
| 173 | Imaging of Urothelial Cancers: What the Urologist Needs to Know. <i>American Journal of Roentgenology</i> , 2011, 196, 1249-1254.   | 2.2 | 19        |
| 174 | Lenalidomide augments the efficacy of bacillus Calmette-Guérin (BCG) immunotherapy in vivo. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1676-1682.   | 1.6 | 19        |
| 175 | Current Use and Promise of Urinary Markers for Urothelial Cancer. <i>Current Urology Reports</i> , 2018, 19, 96.  | 2.2 | 19        |
| 176 | Friend or foe? Role of peroxisome proliferator-activated receptor- $\beta$ in human bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 585-591.   | 1.6 | 18        |
| 177 | A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. <i>Cancer Biology and Therapy</i> , 2013, 14, 812-822.  | 3.4 | 18        |
| 178 | Anterior Fascial Fixation Does Not Reduce the Parastomal Hernia Rate After Radical Cystectomy and Ileal Conduit. <i>Urology</i> , 2014, 83, 1427-1432.  | 1.0 | 18        |
| 179 | Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. <i>Cancer Prevention Research</i> , 2015, 8, 607-613.   | 1.5 | 18        |
| 180 | CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 337.e11-337.e18.  | 1.6 | 18        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guérin therapy: A long-term survival analysis. <i>Oncolmmunology</i> , 2017, 6, e1265719. | 4.6 | 18        |
| 182 | Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e909-e917.   | 1.9 | 18        |
| 183 | Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. <i>IScience</i> , 2020, 23, 101201.  | 4.1 | 18        |
| 184 | Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. <i>European Urology Oncology</i> , 2022, 5, 505-516.   | 5.4 | 18        |
| 185 | Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. <i>Cancer</i> , 2013, 119, 1643-1651.   | 4.1 | 17        |
| 186 | Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. <i>Oncology Reports</i> , 2015, 34, 2738-2744.   | 2.6 | 17        |
| 187 | Smac mimetic with TNF- $\alpha$ targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields. <i>Biochemical Journal</i> , 2016, 473, 99-107.  | 3.7 | 17        |
| 188 | CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 719-729.   | 4.9 | 17        |
| 189 | Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. <i>European Urology Oncology</i> , 2022, 5, 403-411.   | 5.4 | 17        |
| 190 | Clinical significance of ureteric skip lesions™ at the time of radical cystectomy: the M&D Anderson experience and literature review. <i>BJU International</i> , 2014, 113, E28-33.   | 2.5 | 16        |
| 191 | Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1051-1060.   | 1.6 | 16        |
| 192 | RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program. <i>Cell Death Discovery</i> , 2017, 3, 17023.   | 4.7 | 16        |
| 193 | Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 423-431.                                      | 1.6 | 16        |
| 194 | Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018, 4, 512-521.  | 3.1 | 16        |
| 195 | Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. <i>Current Oncology Reports</i> , 2019, 21, 23.  | 4.0 | 16        |
| 196 | Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 119-125.   | 5.4 | 16        |
| 197 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.   |     | 16        |
| 198 | Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 155-167.  | 1.8 | 14        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2021, 206, 577-585. | 0.4 | 14        |
| 200 | Current state of immunotherapy for bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1037-1046.   | 2.4 | 13        |
| 201 | Rise in serum psa of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. <i>Urology</i> , 2004, 63, 1132-1137.  | 1.0 | 13        |
| 202 | Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. <i>Drugs in R and D</i> , 2017, 17, 297-304.  | 2.2 | 13        |
| 203 | The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. <i>Cancer Research</i> , 2017, 77, 6144-6156.   | 0.9 | 13        |
| 204 | Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. <i>Cancers</i> , 2019, 11, 577.  | 3.7 | 13        |
| 205 | The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-GuÃ©rin. <i>BJU International</i> , 2021, 128, 65-71.                           | 2.5 | 13        |
| 206 | Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 796.e1-796.e6.              | 1.6 | 13        |
| 207 | Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 602.e1-602.e9.             | 1.6 | 12        |
| 208 | Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. <i>European Urology</i> , 2018, 74, 405-408.  | 1.9 | 12        |
| 209 | Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. <i>Journal of Sexual Medicine</i> , 2020, 17, 1995-2004.  | 0.6 | 12        |
| 210 | Current Therapy and Emerging Intravesical Agents to Treat Non-muscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 513-529.  | 2.2 | 12        |
| 211 | Treatment of muscle-invasive bladder cancer: progress and new challenges. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1047-1056.  | 2.4 | 11        |
| 212 | Strategies for Optimizing Bacillus Calmette-GuÃ©rin. <i>Urologic Clinics of North America</i> , 2013, 40, 211-218.  | 1.8 | 11        |
| 213 | Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.  | 1.6 | 11        |
| 214 | Strategies to minimize readmission rates following major urologic surgery. <i>Therapeutic Advances in Urology</i> , 2017, 9, 111-119.   | 2.0 | 11        |
| 215 | Salvage topical therapy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 2027-2034.  | 2.2 | 11        |
| 216 | Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-GuÃ©rin. <i>European Urology</i> , 2021, 80, 1-3.   | 1.9 | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2023, 6, 228-232.  | 5.4 | 11        |
| 218 | Controversial issues and optimal management of stage T1G3 bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1283-1294.  | 2.4 | 10        |
| 219 | Pelvic recurrence after radical cystectomy: a call to arms. <i>BJU International</i> , 2015, 116, 172-173.  | 2.5 | 10        |
| 220 | Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. <i>European Urology Focus</i> , 2017, 3, 577-583.  | 3.1 | 10        |
| 221 | The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 2691-2698.   | 2.2 | 10        |
| 222 | Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?. <i>European Urology Oncology</i> , 2021, 4, 510-514.   | 5.4 | 10        |
| 223 | The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020, 203, 283-291. | 0.4 | 10        |
| 224 | Metastatic Epithelioid Hemangioendothelioma of the Penis Managed With Surgery and Interferon- $\alpha$ . <i>Journal of Urology</i> , 2004, 171, 1886-1887.  | 0.4 | 9         |
| 225 | Blebbistatins and mitotic cells exhibit robust macropinocytosis. <i>BioFactors</i> , 2017, 43, 181-186.   | 5.4 | 9         |
| 226 | Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 837-843.   | 1.6 | 9         |
| 227 | Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. <i>World Journal of Urology</i> , 2021, 39, 4295-4303.  | 2.2 | 9         |
| 228 | Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. <i>Cancer Biomarkers</i> , 2022, 33, 151-157.  | 1.7 | 9         |
| 229 | Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 145-146.  | 0.4 | 8         |
| 230 | Contribution of bladder cancer pathology assessment in planning clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 39, 713-719.  | 1.6 | 8         |
| 231 | Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019, 5, 1790.  | 7.1 | 8         |
| 232 | Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. <i>European Urology Oncology</i> , 2019, 2, 286-293.   | 5.4 | 8         |
| 233 | What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. <i>Urology</i> , 2021, 157, 181-187.   | 1.0 | 8         |
| 234 | Trimodal therapy in muscle invasive bladder cancer management. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 650-662.  | 3.9 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. <i>BJU International</i> , 2022, 130, 323-330.   | 2.5 | 8         |
| 236 | Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. <i>European Urology</i> , 2022, 81, 223-228.   | 1.9 | 8         |
| 237 | Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 812-826.  | 1.6 | 7         |
| 238 | Invasive extramammary Paget's disease of the bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva. <i>Gynecologic Oncology Case Reports</i> , 2014, 8, 27-29.  | 0.9 | 7         |
| 239 | Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e99-e111.  | 1.9 | 7         |
| 240 | New horizons in bladder cancer research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 867-885.   | 1.6 | 7         |
| 241 | Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1258-1267.  | 0.4 | 7         |
| 242 | In-vitro cytotoxic effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. <i>Canadian Urological Association Journal</i> , 2015, 9, 109.  | 0.6 | 7         |
| 243 | Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. <i>Journal of Urology</i> , 2022, 207, 551-558.  | 0.4 | 7         |
| 244 | Bladder cancer: imperatives for personalized medicine. <i>Oncology</i> , 2011, 25, 951-8, 960.   | 0.5 | 7         |
| 245 | Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 263-269.   | 0.7 | 7         |
| 246 | Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.  | 3.1 | 7         |
| 247 | All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. <i>Journal of Urology</i> , 2022, 208, 284-291.   | 0.4 | 7         |
| 248 | Perioperative Intravesical Therapy After Transurethral Resection for Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 19-20.   | 0.4 | 6         |
| 249 | Immune Therapies in Non-Muscle Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 5.  | 3.0 | 6         |
| 250 | Optimum management of non-muscle-invasive micropapillary variant urothelial carcinoma: possibility for missed chance of cure?. <i>BJU International</i> , 2016, 118, 349-350.  | 2.5 | 6         |
| 251 | Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. <i>Eur Urol</i> 2016;69:60-9. <i>European Urology</i> , 2016, 69, e121-e122. | 1.9 | 6         |
| 252 | The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview. <i>BJUI Compass</i> , 2020, 1, 87-92.  | 1.3 | 6         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 237.e1-237.e5.             | 1.6 | 6         |
| 254 | Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. <i>Nature Reviews Urology</i> , 2021, , . | 3.8 | 6         |
| 255 | Chemoprevention of superficial bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 799-808.  | 2.4 | 5         |
| 256 | Lymph node density: surrogate marker for quality of resection in bladder cancer?. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 777-779.   | 2.4 | 5         |
| 257 | Fluorescence cystoscopy for nonmuscle invasive bladder cancer. <i>Cancer</i> , 2011, 117, 882-883.   | 4.1 | 5         |
| 258 | The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2016, 34, 1561-1566.   | 2.2 | 5         |
| 259 | Predictors of Response to Intravesical Therapy. <i>Urologic Clinics of North America</i> , 2020, 47, 23-33.  | 1.8 | 5         |
| 260 | Bacillus Calmette-GuÃ©rin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. <i>European Urology Oncology</i> , 2021, 4, 826-828.         | 5.4 | 5         |
| 261 | Converging Roads to Early Bladder Cancer. <i>European Urology</i> , 2020, 78, 127-130.   | 1.9 | 5         |
| 262 | NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?. <i>Nature Reviews Urology</i> , 2020, 17, 491-492.   | 3.8 | 5         |
| 263 | Time interval from transurethral resection of bladder tumour to bacille Calmette-GuÃ©rin induction does not impact therapeutic response. <i>BJU International</i> , 2021, 128, 634-641.  | 2.5 | 5         |
| 264 | Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. <i>World Journal of Urology</i> , 2021, 39, 4143-4149.   | 2.2 | 5         |
| 265 | New discoveries in the molecular landscape of bladder cancer. <i>F1000Research</i> , 2016, 5, 2875.  | 1.6 | 5         |
| 266 | Bladder cancer: 2017 and beyond. <i>Indian Journal of Urology</i> , 2017, 33, 104.   | 0.6 | 5         |
| 267 | Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. <i>European Urology</i> , 2022, 81, 316-317.   | 1.9 | 5         |
| 268 | Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 361-370.   | 2.4 | 5         |
| 269 | Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 176-182.   | 1.9 | 5         |
| 270 | Lymphadenectomy with Robotic Cystectomy. <i>Current Urology Reports</i> , 2013, 14, 59-63.   | 2.2 | 4         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | 1870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY. Journal of Urology, 2013, 189, .                                      | 0.4 | 4         |
| 272 | Innovation in Bladder Cancer Immunotherapy. Journal of Immunotherapy, 2016, 39, 291-297.   | 2.4 | 4         |
| 273 | Secondary Tumors After Urinary Diversion. Urologic Clinics of North America, 2018, 45, 91-99.  | 1.8 | 4         |
| 274 | Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer—Reply. JAMA Surgery, 2019, 154, 186.   | 4.3 | 4         |
| 275 | Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer, 2021, 7, 243-252.  | 0.4 | 4         |
| 276 | Macro and microeconomics of blue light cystoscopy with CYSVIEWA® in non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e7-10.e12.   | 1.6 | 4         |
| 277 | Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.. Journal of Clinical Oncology, 2019, 37, 4530-4530. | 1.6 | 4         |
| 278 | Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement. Cancer Causes and Control, 2022, 33, 613-622.   | 1.8 | 4         |
| 279 | Metastatic penile cancer in a young Caucasian male: Impact of delayed diagnosis. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 130-131.   | 1.6 | 3         |
| 280 | A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nature Reviews Urology, 2006, 3, 472-473.  | 1.4 | 3         |
| 281 | The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients. Bladder Cancer, 2015, 1, 171-179.   | 0.4 | 3         |
| 282 | Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer, 2016, 2, 203-213.  | 0.4 | 3         |
| 283 | Effects of thiazolidinedione in patients with active bladder cancer. BJU International, 2018, 121, 244-251.  | 2.5 | 3         |
| 284 | Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. European Urology Oncology, 2018, 1, 1-2.   | 5.4 | 3         |
| 285 | Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.  | 1.9 | 3         |
| 286 | A Case for Risk-adapted Management of Low-grade Bladder Tumors. European Urology Oncology, 2020, 3, 128-129.   | 5.4 | 3         |
| 287 | Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer. Journal of Geriatric Oncology, 2020, 11, 1118-1124.   | 1.0 | 3         |
| 288 | Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 247-254.   | 1.6 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2020, 154, 208-214.  | 0.7 | 3         |
| 290 | The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. <i>Advances in Therapy</i> , 2021, 38, 1584-1600. | 2.9 | 3         |
| 291 | The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. <i>European Urology</i> , 2021, 79, 437-439.  | 1.9 | 3         |
| 292 | Immune response results from vesigenurtacel-I (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4531-4531.                                    | 1.6 | 3         |
| 293 | Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. <i>Oncotarget</i> , 2017, 8, 88782-88791.  | 1.8 | 3         |
| 294 | Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. <i>BJU International</i> , 2022, 130, 604-610.   | 2.5 | 3         |
| 295 | Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e1-273.e9.   | 1.6 | 3         |
| 296 | Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e1-382.e6.             | 1.6 | 3         |
| 297 | Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guérin instillation masquerading as peritoneal carcinomatosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 352-353.                                       | 1.6 | 2         |
| 298 | Intravesical BCG for bladder cancer. <i>Cancer</i> , 2008, 113, 674-676.   | 4.1 | 2         |
| 299 | Natural Compounds Targeting STAT3 Mediated Inflammation. <i>European Urology</i> , 2016, 69, 405-406.  | 1.9 | 2         |
| 300 | High-grade neuroendocrine carcinoma of the urachus—report of 3 cases. <i>Human Pathology</i> , 2017, 67, 126-133.  | 2.0 | 2         |
| 301 | Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2017, 3, 147-148.  | 0.4 | 2         |
| 302 | It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer—A competing risks analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 39-42.                      | 1.6 | 2         |
| 303 | Intravesical Therapy — BCG and Beyond. <i>Bladder Cancer</i> , 2019, 5, 73-80.   | 0.4 | 2         |
| 304 | Locally advanced prostate cancer imaging findings and implications for treatment from the surgical perspective. <i>Abdominal Radiology</i> , 2020, 45, 865-877.  | 2.1 | 2         |
| 305 | Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease. <i>European Urology</i> , 2021, 79, 105-106.  | 1.9 | 2         |
| 306 | Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. <i>Urology</i> , 2021, 147, 127-134.  | 1.0 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 128, 568-574.  | 2.5 | 2         |
| 308 | Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. <i>Indian Journal of Urology</i> , 2008, 24, 77.  | 0.6 | 2         |
| 309 | Immunotherapy in Bacillus Calmette-Guérin (BCG) unresponsive nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2021, 31, 160-169.   | 1.8 | 2         |
| 310 | Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022, 8, 113-117.   | 0.4 | 2         |
| 311 | Treatment of bladder cancer in cardiac transplant patients. <i>International Urology and Nephrology</i> , 2007, 38, 477-479.   | 1.4 | 1         |
| 312 | Is Repeat Transurethral Resection Needed for Minimally Invasive T1 Urothelial Cancer?. <i>Journal of Urology</i> , 2011, 186, 788-789.   | 0.4 | 1         |
| 313 | Taking the next step—Advancing bladder cancer management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 435-436.  | 1.6 | 1         |
| 314 | Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? <i>Eur Urol</i> 2016;69:201-2. <i>European Urology</i> , 2016, 69, 203. | 1.9 | 1         |
| 315 | Should we care more about SPARE?. <i>BJU International</i> , 2017, 120, 605-606.   | 2.5 | 1         |
| 316 | Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 403-404.   | 1.6 | 1         |
| 317 | How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?. <i>European Urology Oncology</i> , 2020, 3, 252-257.  | 5.4 | 1         |
| 318 | Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy. <i>European Urology Open Science</i> , 2020, 19, 27-36.  | 0.4 | 1         |
| 319 | Use of psychotropic drugs among older patients with bladder cancer in the United States. <i>Psycho-Oncology</i> , 2021, 30, 832-843.   | 2.3 | 1         |
| 320 | Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. <i>European Urology Oncology</i> , 2021, , .                            | 5.4 | 1         |
| 321 | Urologists, You™I Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 268-272.   | 5.4 | 1         |
| 322 | Oncologic Equipose Between Robotic and Open Radical Cystectomy. <i>Journal of Endourology</i> , 2021, 35, 1168-1176.   | 2.1 | 1         |
| 323 | Clinical Management. , 2016, , 143-151.  |     | 1         |
| 324 | BCG shortage: Reassessing the clinical viability of Bacillus Calmette-Guérin (BCG) after reconstitution.. <i>Journal of Clinical Oncology</i> , 2020, 38, 534-534.   | 1.6 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 325 | Should Patients With Non-muscle-invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?. BJU International, 2021, , .   | 2.5 | 1         |
| 326 | Editorial Comment. Journal of Urology, 2009, 182, 2630-2630.   | 0.4 | 0         |
| 327 | Bladder Cancer and Upper Tracts. , 2012, , 311-333.  |     | 0         |
| 328 | Reply. Urology, 2014, 83, 1432.  | 1.0 | 0         |
| 329 | Predicting Response to Bacillus Calmette-Guérin: Time to Look Beyond the Ages. European Urology, 2014, 66, 702-703.  | 1.9 | 0         |
| 330 | Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.e1-108.e4). Urologic Oncology: Seminars and Original Investigations, 2015, 33, 335-336.  | 1.6 | 0         |
| 331 | Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. <a href="http://dx.doi.org/10.1016/j.eururo.2015.05.050">http://dx.doi.org/10.1016/j.eururo.2015.05.050</a> . European Urology, 2015, 69, e127. | 1.9 | 0         |
| 332 | Editorial comment. Current Opinion in Urology, 2018, 28, 555-556.  | 1.8 | 0         |
| 333 | New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. Bladder Cancer, 2018, 4, 339-342.   | 0.4 | 0         |
| 334 | Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 815-817.   | 1.6 | 0         |
| 335 | Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 855-857.   | 1.6 | 0         |
| 336 | Reply by Authors. Journal of Urology, 2021, 205, 1620-1621.  | 0.4 | 0         |
| 337 | B2B: Bladder Cancer Summary. Soci t  Internationale D'urologie Journal, 2021, 2, S7-S16.   | 0.4 | 0         |
| 338 | Reply by Authors. Journal of Urology, 2021, 206, 1267.   | 0.4 | 0         |
| 339 | Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu rin: Implications for Clinical Trial Design. Reply.. Journal of Urology, 2021, , 101097JU00000000000002238.   | 0.4 | 0         |
| 340 | Urothelial Carcinoma with Variant Histology: Sarcomatoid, Plasmacytoid, and Micropapillary. , 2016, , 95-108.  |     | 0         |